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Abstract
Markers of monocyte activation play a critical role in atherosclerosis, but little is known about the
genetic influences on cellular levels. Therefore, we investigated the influence of genetic variants
in monocyte differentiation antigen (CD14), toll-like receptor-4 (TLR4), toll-like receptor-2
(TLR2), and myeloperoxidase (MPO) on monocyte surface receptor levels. The study sample
consisted of 1,817 members of a biracial cohort of adults from the Atherosclerosis Risk in
Communities Carotid MRI Study. Monocyte receptors were measured using flow cytometry on
fasting whole blood samples. TLR2 rs1816702 genotype was significantly associated with
CD14+/TLR2+ percent of positive cells (%) and median fluorescence intensity (MFI) in whites
but not in blacks (p < 0.001). Specifically, the presence of the minor T-allele was associated with
increased receptor levels. In blacks, TLR4 rs5030719 was significantly associated with CD14+/
TLR4+ monocytes (MFI) with mean ± SE intensities of 16.7 ± 0.05 and 16.0 ± 0.14 for GG and
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GT/TT genotypes, respectively (p < 0.001). Variants in TLR2 and TLR4 were associated with
monocyte receptor levels of TLR2 and TLR4, respectively, in a biracial cohort of adults. To our
knowledge, this is the first study to look at associations between variants in the toll-like receptor
family and toll-like receptor levels on monocytes.
Introduction
Monocytes and macrophages are integral components in the initiation and progression of
atherosclerosis (Swirski et al. 2009). Recent work in mice and humans has identified the
importance of surface receptor levels in regulating cellular function (Geissmann et al. 2003;
Swirski et al. 2009). In humans, monocytes are currently categorized based on their
expression of surface receptors, CD14 and CD16. Monocytes expressing CD14 have been
labeled inflammatory monocytes, while monocytes expressing CD16 have been labeled
resident monocytes. Inflammatory monocytes express additional surface receptors that
respond to inflammatory chemokines, including toll-like receptors (TLRs) and
myeloperoxidase (MPO). Specifically, the TLR4/nuclear factor-κB pathway has been
implicated in inflammatory plaque activation by lipids and plaque destabilization (Kiechl et
al. 2003).
CD14 is a potent cofactor enhancing the recognition of TLR2 and TLR4 ligands and high
levels of CD14 were associated with increased risk of cardiovascular events and death in
dialysis patients (Heine et al. 2008), intima media thickness (IMT; Ulrich et al. 2008), and
myocardial infarction (MI; Ozdogru et al. 2007). TLRs mediate the synthesis of
proinflammatory cytokines and are upregulated in atherosclerotic lesions (Schoneveld et al.
2008) and in animal models of atherosclerosis (Li and Sun 2007; Mullick et al. 2005;
Schoneveld et al. 2005). Studies utilizing human artery tissue have shown significant
elevations of TLR1, TLR2, and TLR4 levels in atherosclerotic lesions compared to normal
arteries (Edfeldt et al. 2002). Patients with acute MI and unstable angina had higher levels of
circulating TLR4 compared to those with stable angina and controls (Ishikawa et al. 2008;
Methe et al. 2005). Higher TLR4 levels are also associated with heart failure after MI (Satoh
et al. 2006) and surface levels of TLR2 and TLR4 are increased in type 1 diabetic patients
(Devaraj et al. 2008). Increased TLR4 expression was also observed at the site of plaque
rupture (Ishikawa et al. 2008). Furthermore, recent evidence suggests that variants in TLR
genes may be associated with IMT, although the data are inconclusive (Hernesniemi et al.
2008; Labrum et al. 2007; Netea et al. 2004). MPO is a peroxidase in the cytoplasm that
breaks down hydrogen peroxide (Klebanoff 2005). Circulating monocytes contain MPO but
lose expression in the transition to a macrophage. Higher circulating levels of MPO have
been associated with the presence of coronary artery disease (CAD; Zhang et al. 2001) and
increased risk of subsequent coronary events in patients with acute coronary syndromes
(Baldus et al. 2003).
Despite progress in identifying the importance of cell surface receptors as key regulators of
cell function, the field has been partly limited by the lack of conservation of antigens
between mouse and humans. Specifically, CD14 and CD16 do not exist in the mouse.
Additionally, the flow cytometry methods used to measure these markers are expensive and
labor intensive, and require highly skilled personnel. Thus, few large-scale studies have
employed this technique. Therefore, little is known about the influence of genetic variants
on levels of these markers in monocytes. Thus, insight into the regulation of the levels of
these surface receptors is important. We propose to test the hypothesis that the variants in
the structural genes for CD14, TLR2, TLR4, and MPO were associated with altered
monocyte surface receptor levels of these proteins in a biracial cohort of adults from the
Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study.
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The study sample consisted of 2,066 members of the ARIC Study who participated in the
ARIC Carotid MRI Study in 2004–2005. ARIC is a cohort study of cardiovascular disease
that recruited 15,792, men and women, mainly blacks and whites, from four US
communities: Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and
Washington County, MD. The ARIC Study has been described in detail elsewhere (1989).
In 2004–2005, ARIC participants from the four communities were recruited to participate in
the Carotid MRI Study under a stratified sampling design. The sampling goal was to recruit
1,200 participants with high values of maximum carotid artery IMT, and 800 individuals
randomly sampled from the remainder of the carotid IMT distribution. The high values of
IMT were those above field-center-specific cut points, which were adjusted over the
recruitment period to achieve the sampling goal. Maximum IMT was based on
measurements over six sites, left and right, common, bifurcation, and internal at each
subject's last ARIC ultrasound examination in the 1990s. A total of 4,307 ARIC cohort
members were contacted for study, of which 1,404 refused, 837 were ineligible to undergo
MRI, and 2,066 whites and blacks were examined. This study was approved by the
institutional review board at each field center and all subjects gave informed consent.
Measurements
A fasting whole blood sample was collected into Cyto-Chex® BCT vacutainer tubes
(Streck, Omaha, NE). The BCT tubes were inverted eight times, stored briefly at room
temperature, and shipped overnight in temperature-stabilizing packages to the flow
cytometry laboratory at the University of Texas Health Science Center at Houston. The
containers had sufficient insulating capacity to maintain the transportation temperatures of
the specimens. Immediately upon receipt, the laboratory prepared and analyzed samples
within 24 h of blood drawing using a Coulter® Epics™XL™ flow cytometer (Beckman
Coulter, Inc., Miami, FL). The protocols, antibodies, and the reproducibility of the methods
are described in detail elsewhere (Catellier et al. 2008). Briefly, flow cytometry measures
fluorescence per cell using the principles of light scattering, light excitation, and emission of
fluorochrome molecules. The flow cytometry measures for the ARIC Carotid MRI Study
included platelet and monocyte markers, myeloperoxidase, and platelet aggregates with
monocytes that were shown in preliminary studies to be reproducible. Given our aim of
investigating monocyte activation, the variables for this analysis were restricted to the
markers of monocyte activation and included myeloperoxidase (MPO); toll-like receptors
(TLR) 2 and 4; CD14 (lipopolysaccharide, LPS, receptor); P-selectin glycoprotein ligand-1
(PSGL-1, CD162); and pan-leukocyte marker (CD45). Data are presented as proportions of
cells expressing antigen (%) and/or the relative levels of antigen levels assessed by the
median fluorescence intensity (MFI). Coefficients of variation (CV) for both % of positive
cells and MFI are shown in Table 1 for replicate samples drawn from a single venipuncture
(n = 103). Values range from 2.0 to 9.5. Complete results for intra-individual variability and
reliability of these measures in the ARIC Carotid MRI Study have been previously
published (Catellier et al. 2008).
Height was measured while participants were standing without shoes, heels together against
a vertical mounted ruler. A Detecto Platform Balance was used to measure weight. BMI was
calculated as weight (kg)/height2 (m2). Waist circumferences were measured at the level of
the umbilicus with the participant standing erect. Plasma total cholesterol and triglycerides
were measured by enzymatic methods and HDL cholesterol after dextran sulfate–
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magnesium precipitation of non-HDL lipoproteins. LDL cholesterol was calculated via the
Friedewald equation.
Genotyping
For this study, we evaluated tagSNPs in four structural genes, CD14, MPO, TLR2, and
TLR4, corresponding to the flow cytometry measurements available. TagSNPs within
CD14, TLR2, TLR4, and MPO were derived using the Haploview Program based on two
sources of SNPs: the Caucasian (CEU) and Yoruban (YRI) population from the
International HapMap project. The data were analyzed in a race-specific manner on a gene
by gene basis using the gene definitions provided by the HapMap database. Known replicate
samples were included in the plate set for genotyping and concordance of these duplicated
samples for all SNPs was 99.998. The authors had full access to the data and take
responsibility for its integrity. All authors have read and agree to the manuscript as written.
Statistical analysis
We excluded those missing all flow cytometry data, missing all SNP data (n = 166 for both
groups), taking chemotherapy or steroids (n = 75) or not consenting to use of DNA (n = 8),
which left 1,817 for study. All analyses were based on methods suitable for stratified
random sample methods, with samples weighted by the inverse of the sampling fractions in
the eight strata (4 communities × 2 IMT groups). The sample fractions were based on those
persons actually screened for participation. Those who participated (non-refusing eligible)
were analyzed as a sub-population (domain) of those invited in calculating variances and
confidence intervals of estimators as well as in modeling. Basic statistics of flow cytometry
phenotypes were calculated by race groups, using SAS version 9.1. Genotype frequencies
were estimated using SUDAAN CROSSTAB, and allele frequencies were calculated from
genotype frequencies, as P(AA) + P(Aa)/2 for allele A, where P(AA) and P(Aa) are the
weighted frequencies of AA and Aa. Hardy–Weinberg equilibrium was tested using
weighted genotype frequencies and their covariance matrix, applying the delta method to get
the test statistic. Means of flow cytometry measurements from different genotypes were
further evaluated by linear models, using SUDAAN, with appropriate tests for the
significance of differences in means among genotype groups. Linear regression and testing
were carried out separately for each combination of race and SNP. Different linear models
were implemented to estimate: (1) unadjusted means; (2) means adjusted for age and sex;
(3) and means adjusted for age, sex, triglycerides, HDL, LDL, waist, BMI, use of cholesterol
lowering medications, and current and former smoking status. SNPs with a race-specific
minor allele frequency < 1% were not analyzed in that race, which eliminated four race-SNP
combinations from the analysis. Minor allele homozygotes and heterozygotes were
combined when the number of subjects in a race-specific geno-type group was <10. To
correct for multiple comparisons, we used Bonferroni corrections based on the total number
of race-SNP combinations (2 races × 15 SNPs + 1 race × 4 SNPs) and set a threshold of p <
0.001 (0.05/34) to deter mine statistical significance. TLR4 SNPs rs4986790 and rs4986791
affect the extracellular domain of the receptor (Arbour et al. 2000; Lorenz et al. 2001). To
investigate the co-segregation of two functional SNPs in TLR4 (rs4986790 and rs4986791),
in whites we compared the following genotype combinations for rs4986790 and rs498691,
respectively, AA/CC and AG or GG/CT and in blacks AA/CC and AG or GG/CC.
Results
Baseline characteristics are shown in Table 2 by race. Differences by race and sex for the
monocyte phenotypes have been described elsewhere (Folsom et al. 2009). Allele
frequencies for CD14, MPO, TLR2, and TLR4 are listed in Table 3 including the assessment
of HWE. The description of each SNP is listed in Online Table 1. Online Tables 2–21
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present unadjusted means for monocyte phenotypes by race as the adjustment for sex did not
materially alter the associations. Furthermore, unless otherwise noted, the addition of other
covariates also did not materially change the associations.
TLR2 rs1816702 genotype was significantly associated with CD14+/TLR2+ (% and MFI) in
whites, Table 4, but not in blacks (p > 0.4, Online Table 3). Specifically, the presence of the
minor T-allele was associated with increased receptor levels on the surface of the
monocytes. This SNP was not associated with any of the covariates tested in whites (data
not shown). However, adjustment for lipids, waist circumference, BMI, and smoking
strengthened the association. In blacks, TLR4 rs5030719 was significantly associated with
CD14+/TLR4+ monocytes (MFI) with mean ± SE intensities of 16.7 ± 0.05 and 16.0 ± 0.14
for GG and GT/TT genotypes, respectively (<0.001, Table 5). A similar pattern was seen
with the presence of the T-allele associated with lower mean percentage of positive cells,
albeit not significant (p = 0.05). In whites, rs5030719 is monomorphic.
Two other SNPs appear to be associated with monocyte phenotypes although neither met the
a priori defined significance threshold. TLR4 rs4986790 was associated with CD14+/
TLR4+ cells (%) in blacks with means of 16.7 ± 0.06 for AA and 16.4 ± 0.11 for AG/GG
genotypes (p = 0.004), Online Table 10. MPO rs28730837 was associated with monocyte
levels of MPO (MFI) in whites with mean intensities of 90.2 ± 0.80 and 79.9 ± 3.59 in CC
and CT/TT genotypes, respectively p = 0.005), Online Table 21. In blacks, MPO rs8067377
was associated with monocyte levels of MPO (MFI) with mean intensities of 104.2 ± 1.8
and 93.0 ± 3.8 in CC and CT/TT genotypes, respectively (p = 0.008), Online Table 20. No
significant differences were observed for the genotype combinations of rs4986790 and
rs498691, Online Tables 22–23.
Discussion
The major findings of this population-based study were that genetic variants in TLR2 and
TLR4 were associated with monocyte surface receptor levels of TLR2 and TLR4,
respectively, in a biracial cohort of adults. Moreover, these associations between genotype
and phenotype were unique to whites (in the case of TLR2) and blacks (in the case of
TLR4). This study takes the first step in identifying genetic determinants of surface receptor
levels. Given the economic and technical issues related to measuring these phenotypes in
large scale studies, identifying genetic variants related to phenotypic levels may enhance our
ability to investigate these cellular pathways and atherosclerosis. Epidemiologic studies
investigating potential associations between bacterial infection and atherosclerosis provide
the initial evidence linking TLR activation and vessel disease (Kalayoglu et al. 2002). In this
investigation, we report that TLR2 rs1816702 and TLR4 rs5030719 were associated with
monocyte phenotypes in whites and blacks, respectively.
TLR2 rs1816702 is located within intron 2 and is in tight linkage disequilibrium (LD) with
rs4696483, also located in intron 2 (r2 = 0.93 HapMap CEU Data). The T-allele was less
common in whites (f = 0.11) compared to blacks (f = 0.42). In whites, the T-allele was
associated with an increased percentage of monocytes positive for TLR2. The biological
effect of enhanced TLR2 levels in a greater percentage of monocytes positive for TLR2 is
not known. In animal models, TLR2−/− ApoE −/− mice exhibited decreased atherosclerosis,
and reduced monocyte chemoattractant protein-1 (MCP-1) production upon stimulation of
the TLR2 ligand (Liu et al. 2008). TLR2 −/− on a LDLr−/− background also exhibited
decreased atherosclerosis (Mullick et al. 2005). These studies suggest that TLR2 is
atherogenic. However, controversy exists as to the role of TLR2 in the monocytes in these
studies. Previous genetic work in humans suggested that a frequent TLR2 SNP, rs5743708
(Arg753Gln), resulted in a non-functional receptor. Patients with the G allele were protected
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against restenosis compared to A-carriers (Hamann et al. 2005). Future studies will be
needed in both murine models and humans to better understand the role of TLR2 within
different cell types and how risk alleles may alter the biology of TLR2 structure and
function.
TLR4 rs5030719 encodes a glutamine to histidine substitution in exon 3 and was only
polymorphic in blacks (T-frequency = 0.03). Carriers of the minor T-allele at this site had
lower levels of CD14+/TLR4+ cells compared to homozygotes for the wild-type allele.
TLR4 rs4986790 encodes an aspartic acid to glycine substitution in exon 3 and the minor G
allele was modestly associated with lower levels of CD14+/TLR4+ monocytes (MFI) (p =
0.004 in blacks and 0.04 in whites). However, we did not observe a relationship with
genotype combinations of these two SNPs with monocyte levels. TLR4 rs4986790 is in
moderate LD with rs5030719 (r2 = 0.49 HapMap Yoruba data). Previous work investigating
atherosclerotic phenotypes and TLR4 polymorphisms has focused on rs4986790 and a co-
segregating variant that was rare (frequency < 1%) in blacks in our study sample
(rs4986791, Thr399Ile). Both TLR4 rs4986790 and rs4986791 are functional variants that
affect the extracellular domain of the receptor (Arbour et al. 2000; Lorenz et al. 2001).
TLR4 rs4986790 has been reported to be associated with carotid artery elasticity
(Hernesniemi et al. 2008) and both increased and decreased IMT (Kiechl et al. 2002), albeit
inconsistently for the later (Hernesniemi et al. 2008; Norata et al. 2005). The majority of
studies found a positive effect of the minor G-allele attributed to an attenuated inflammatory
response, corroborating our finding of reduced receptor levels (Hernesniemi et al. 2008;
Kiechl et al. 2002). Enquobahrie et al. (2008) reported that TLR4 haplotypes were
associated with MI risk and specifically the minor allele of rs1927911 was associated with a
12% lower MI risk. In aggregate, these results, including our novel finding with TLR4+
monocyte levels, suggest that the TLR4 gene seems to play a role in the immune response
influencing atherosclerosis. Work from the lab of Alan Tall and others have found that
dysregulation of cholesterol efflux from macrophages alters the inflammatory profile in
response to TLR ligands (Sun et al. 2009; Yvan-Charvet et al. 2010a, b, c; Yvan-Charvet et
al. 2008). These findings suggest that functional variants in TLR4 may be important in
mediating inflammatory responses to cholesterol and TLR ligands. Furthermore, these
results consistently find beneficial effects of minor alleles on atherosclerosis phenotypes,
possibly the result of attenuated function of the protein leading to a diminished immune
response. Animal models support that this assertion as deficiency in TLR4 is associated with
reductions in aortic atherosclerosis (Michelsen et al. 2004), lesion formation (Vink et al.
2002), and arterial remodeling (Hollestelle et al. 2004).
MPO rs28730837 encodes an alanine to valine substitution in exon 6 and the minor allele
(T) was modestly associated in whites with lower levels of MPO in monocytes (p = 0.005).
This SNP was monomorphic in blacks. Conversely, rs8067377, an intronic SNP, was
associated in blacks and monomorphic in whites. However, again we see lower levels of
MPO levels in monocytes associated with the minor allele (p = 0.008). Previously published
MPO gene variant studies have focused primarily on a promoter SNP (−463G/A) not
genotyped in our study. This SNP has been associated with carotid artery IMT (Makela et al.
2008) and in giant cell arteritis (Salvarani et al. 2008).
Differences in the genetic variation across populations in these immune signaling genes may
explain the population-specific results observed. Mounting evidence suggests that
evolutionary pressure due to infectious disease is the driving force of population differences
in TLR variants (Ferwerda et al. 2007, 2008; Velez et al. 2009, 2010). For TLR2, numerous
functional variants have been identified that differ in frequency by race and have been
shown to be associated with susceptibility to infection (Merx et al. 2007; Velez et al. 2010;
Yim et al. 2004). In the case of TLR4, the majority of the non-synonymous variation is
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located in the third exon that encodes the region of the protein involved in pathogen
recognition (Smirnova et al. 2001). Of the four non-synonymous variants in exon 3
genotyped in this study, two were monomorphic in whites. Previous studies of population
differences have focused on TLR4 rs4986790 and rs4986791. In Africans, the minor allele
of rs4986790 is relatively common with a frequency of 10–18%, whereas the minor allele of
rs4986791 is rare. The rs4986790 variant not only shows an enhanced immune response that
increases susceptibility to septic shock (Agnese et al. 2002) but may also protect against
mortality in severe malaria (Mockenhaupt et al. 2006). Although these studies did not
include the two significant SNPs observed in our study, collectively they provide strong
evidence of population-specific differences in gene function.
Despite the novel findings, this study has limitations. First, flow cytometry is a sensitive and
reproducible method for detecting receptor surface levels; however, this method is unable to
determine if there are changes in the function of the receptor. Secondly, monocytes are
produced in the bone marrow and move into the subendothelial space. Thus, measurements
in monocyte populations are a moving target and flow cytometry captures only a single
snapshot. Finally, in the present analysis, we were able to measure CD14, MPO, TLR2, and
TLR4 levels on specific antibody characterized cell populations. Recent work suggests that
CD16 may also be an important biomarker (Swirski et al. 2009) but was not measured in our
study. Furthermore, CD14+ inflammatory monocytes express high levels of additional
surface receptors that were not measured.
In this novel investigation, we identified genetic variants in toll-like receptor genes, TLR2
and TLR4, that were associated with monocyte surface receptor levels of these proteins.
Secondly, we identified a modest association with MPO variants and MPO cell surface
levels in monocytes. Further studies are needed to understand the function of these variants
on protein structure and function, the importance of these variants in other populations, and
the relationship of genetic variants in these genes and cardiovascular outcome.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Coefficients of variation (CV) for replicate samples drawn from a single venipuncture (n = 103 replicate pairs)
Monocyte markers Alternate name CV
% MFI
CD14 Lipopolysaccharide (LPS) receptor 3.7
CD14/TLR2 Toll-like receptor-2 4.4 2.0
CD14/TLR4 Toll-like receptor-4 2.0 2.6
CD14/CD41/TLR4 GPIIb (αIIb) 9.5 6.9
CD14/CD162 P-selectin glycoprotein ligand-1 (PSGL-1) 3.3
CD14/TLR2/CD162 4.3 2.0
CD14/COX-2 1.3 7.8
CD45 Pan-leukocyte marker 3.8
CD45/MPO Myeloperoxidase 8.3
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Table 2
Baseline characteristics of subjects genotyped by racial group (means ± SD or percentage)
Variable Blacks Whites p value
Male (%) 36 47 0.001
Age (years) 69 ± 5 71 ± 5 <0.001
Monocyte phenotypes
 CD14+ (MFI) 120 ± 22 109 ± 20 <0.001
 CD14+/TLR2+ (%) 56 ± 10 64 ± 12 <0.001
 CD14+/TLR2+ (MFI) 13 ± 0.80 14 ± 1.5 <0.001
 CD14+/TLR4+ (%) 64 ± 3.3 65 ± 4.2 <0.001
 CD14+/TLR4+ (MFI) 17 ± 0.92 16 ± 1.0 <0.001
 CD14+/CD41+/TLR4+ (%) 12 ± 2.6 11 ± 2.7 <0.001
 CD14+/CD41+/TLR4+ (MFI) 49 ± 6.6 46 ± 5.8 <0.001
 CD14+/CD162+ (MFI) 114 ± 14 111 ± 15 0.001
 CD14+/TLR2+/CD162+ (%) 57 ± 10 65 ± 11 <0.001
 CD14+/TLR2+/CD162+ (MFI) 13 ± 0.81 14 ± 1.7 <0.001
 CD14+/COX2+ (%) 98 ± 2.7 98 ± 3.6 0.60
 CD14+/COX2+ (MFI) 17 ± 2.9 17 ± 2.8 0.31
 CD45+ (MFI) 71 ± 9.8 76 ± 10 <0.001
 CD45+/MPO+ (MFI) 102 ± 28 17 ± 2.8 <0.001
 Triglycerides (mg/dL) 127 ± 61 158 ± 90 <0.001
 HDL cholesterol (mg/dL) 51 ± 14 50 ± 15 0.122
 LDL cholesterol (mg/dL) 124 ± 36 112 ± 35 <0.001
 Waist circumference (cm) 106 ± 15 100 ± 14 <0.001
 BMI (kg/m2) 31 ± 6 29 ± 5 <0.001
 Current smoking (% yes) 10 7 0.009
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Table 3
Allele frequencies calculated using weighted counts by racial group (%)
SNP (allele) Blacks Whites
CD14
rs4914 (G) 7 12
TLR2
rs1816702 (T) 42 11
rs1898830 (G) 11* 35
rs3804099 (T) 41 56
rs3804100 (C) 6 7
rs11938228 (A) 13 37
TLR4
rs1927907 (A) 28* 15
rs1927911 (C) 37 73
rs4986790 (G) 8 6
rs4986791 (T) 0.9 7
rs5030717 (G) 18 12
rs12344353 (C) 14 6
rs5030718 (A) 3 0
rs5030719 (T) 3 0
rs5030728 (A) 13 31
rs11536869 (G) 0.3 4*
MPO
rs2071409 (C) 14 15
rs7208693 (A) 18 8*
rs8067377 (T) 9 0.1
rs28730837 (T) 0.3 2*
*
Not in Hardy–Weinberg Equilibrium (p < 0.05)
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Table 5
Unadjusted means and standard errors of TLR4+ markers, percent of positive cells (%) and median
fluorescence intensity (MFI), by TLR4 rs5030719 in blacks
Monocyte markers Unit GG (n = 409) GT/TT (n = 21) Unadjusted p value
CD14+/CD41+/TLR4+ % 11.7 ± 0.15 11.3 ± 0.51 0.44
MFI 48.6 ± 0.40 49.2 ± 1.64 0.70
CD14+/TLR4+ % 64.2 ± 0.20 63.0 ± 0.56 0.05
MFI 16.7 ± 0.05 16.0 ± 0.14 <0.00001
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